Cyrcadia, Inc. Announces ClinicalTrials.gov Listing for Its Entry into Clinical Trials for Wearable Breast Cancer Detection Device

Reno, Nev. Aug. 11, 2015 — Cyrcadia, Inc. (“Company”) announces its clinical trial listing on ClinicalTrials.gov for its wearable breast cancer early detection device at El Camino Hospital, in Mountain View, California and upcoming additional clinical study sites. ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, currently holding registrations from over 130,000 trials from more than 170 countries in the world. “We are enthused that we have initiated the El Camino Hospital trial in Mt. View, CA and have now finalized the ClinicalTrials.gov registry. We look forward to the additions of The James Cancer Hospital at The Ohio State University and the Canary Center at Stanford’s upcoming inclusion into our early breast cancer screening trials,” says Rob Royea, President of Cyrcadia, Inc. For those interested in learning more about the Cyrcadia clinical studies, ClinicalTrials.gov is the registry to use including all details about the study and its status. It is the only location where Cyrcadia will divulge information about the studies and will update the registry from time to time. All information desired about the clinical studies can be obtained there and will not otherwise be divulged by Cyrcadia, its staff or other related parties. All details about the study including descriptions, eligibility and contacts can be obtained there. Please follow this link: ClinicalTrials.gov/Cyrcadia or go to the clinicaltrials.gov website using the identifier NCT02511301 to learn more and follow progress of the study as it is reported. Utilizing its previous FDA cleared device as a...

Cyrcadia, Inc. Enters Clinical Trials for Wearable Breast Cancer Detection Device

Reno, Nev. (PRWEB)July 07, 2015 Cyrcadia, Inc. (“Company”) announces it is entering into a clinical trial for its wearable breast cancer early detection device and is enrolling the first clinical trial participants at El Camino Hospital, in Mountain View, California. Utilizing its previous FDA cleared device as a predicate, Cyrcadia Health™ (a division of Cyrcadia, Inc.) is combining the Company’s fourth generation, wearable device technology, made by Flextronics, and the SalesForce database software, to track the clinical results. “We are targeting both the 70% of the population that undergo biopsies on non-cancerous tissue resulting from mammographic referral, as well as mass screening of patients with dense breasts,” said Rob Royea, president of Cyrcadia Health. “Patients with dense breast tissue have a higher propensity for cancer. Furthermore, mammography is challenged by detecting cancer in dense breast tissue as it can mask cancer cells and lesions.” Following successful completion of the clinical trials, the Company intends to produce a wearable, smart phone enabled technology, called the iTBraTM, which will utilize a comfortable data collection device placed under a bra to collect from two to twelve hours of breast cell data (dynamic cell chaos). Circadian rhythm-based temperature variances of cell cycles are then measured through a patented process to identify abnormalities at the earliest stages of cellular change, the results of which are transferred through a smart device to a global cancer library, where advanced analytical analysis occurs, and results are communicated back to the patient and physician. “El Camino Hospital is pleased to be involved in Cyrcadia Health’s research study to evaluate this potential new technology,” said Katherine Sutherland, MD, co-investigator...